Europe Oligonucleotide Synthesis Market

The oligonucleotide synthesis market in Europe is projected to reach USD 7.49 billion by 2030 from USD 3.17 billion in 2025, at a CAGR of 18.7% during the forecast period.

One of the major factors that boosts the market for oligonucleotide synthesis in Europe is the strong backing from governments and institutions in the form of genomics, precision medicine, and life sciences research. The public funding schemes in the EU have been the source of continuous sequencing and molecular biology ventures at universities, genome centers, and translational research labs. Consequently, the demand is stable for primers, probes, adapters, indexing oligos, and custom DNA and RNA that are used in PCR and NGS workflows. This continuous research endeavor leads to the steady use of research-grade oligonucleotides in the region.

To know about the assumptions considered for the study download the pdf brochure

The oligonucleotide synthesis market in Europe is competitive. Prominent players in this market include Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), and LGC Limited (UK), among others.

In February 2024, Merck opened a new distribution center for its life science business in Brazil with an investment of USD 21.75 million (EUR 20 million) to meet the growing demand for life science products and services in the LATAM region. In November 2023, LGC Biosearch Technologies, a business unit of LGC Limited, acquired PolyDesign to enhance its oligonucleotide synthesis capabilities using PolyDesign's frit technology.

Thermo Fisher Scientific Inc. is one of the leading players in the oligonucleotide synthesis market in Europe. The company designs and manufactures a wide range of molecular workflow products for research applications, such as custom DNA and RNA oligonucleotides, PCR and qPCR reagents, and enzymes and controls. It is a well-known fact that European scientific labs heavily rely on their products for primer and probe-based assays, which require consistent performance and a reliable supply.

Danaher Corporation is a leading market player in Europe for oligonucleotide synthesis for research oligonucleotides, primarily through Integrated DNA Technologies (IDT), which is widely used for custom DNA and RNA synthesis across academic, clinical, and diagnostic laboratories. Its oligos support routine molecular workflows, including qPCR primers and probes for infectious disease, oncology, and genetic testing. The company also supplies NGS adapters and index primers used in sequencing library preparation.

Biogen has been a key player in the oligonucleotide synthesis market in Europe, largely due to blockbuster drugs like Spinraza (nusinersen), the first approved ASO for spinal muscular atrophy (SMA), which generated strong sales across the continent. Recent developments, such as the CHMP positive opinion for a high-dose Spinraza regimen in late 2025 and the launch of Qalsody (tofersen) for ALS, are ramping up demand for large-scale GMP-grade oligonucleotides to support ongoing manufacturing and delivery innovations.

Alnylam Pharmaceuticals is experiencing strong growth in the oligonucleotide synthesis market in Europe through its RNAi therapy portfolio, which encompasses drugs like Amvuttra (vutrisiran) and Onpattro (patisiran). These posted strong European sales in 2025. Amvuttra's recent approvals for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the EU, the UK, and other regions have observed a surge in patient uptake.

Market Ranking

The oligonucleotide synthesis market in Europe is competitive. For research and diagnostic oligos, Danaher is a leading supplier through Integrated DNA Technologies (IDT). IDT is widely used across European universities, clinical labs, and assay developers for custom DNA/RNA oligos, routine qPCR primers/probes, and NGS adapters/indexing oligos. The brand is valued for consistent lot quality and dependable delivery for repeat workflows. Thermo Fisher also holds a strong position in Europe due to broad workflow pull-through. Its strength comes from bundling across PCR/NGS consumables, strong distribution, and deep presence in research and clinical labs. For oligo-based drugs, Alnylam is a key demand anchor through its siRNA medicine portfolio, which drives recurring GMP manufacturing cycles and commercial-scale supply needs that influence European sourcing. Biogen similarly supports therapeutic pull through its antisense (ASO) medicines, including long-running products that require consistent, high-purity oligo drug substance.

Related Reports:

Europe Oligonucleotide Synthesis Market by Product ((Drugs (ASO, siRNA), Synthesized Oligos (Product (Primers, Probes)), Type ((Custom, Predesigned), Reagents, Equipment), Application (Therapeutic, Research, Diagnostics) - Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com